Tarsus Pharmaceuticals develops targeted therapies for diseases with high unmet medical needs, including the first FDA-approved treatment for Demodex blepharitis, XDEMVY® (lotilaner ophthalmic solution) 0.25%. The company is advancing a robust pipeline of investigational treatments for conditions such as papulopustular rosacea and Lyme disease, addressing significant gaps in available therapies.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PAFounders
Product
Problem
Many diseases lack targeted therapies, leaving significant unmet medical needs for patients. Conditions like Demodex blepharitis, rosacea, and Lyme disease often have limited or no approved treatment options, impacting patient quality of life.
Solution
Tarsus Pharmaceuticals focuses on developing innovative therapies to address diseases with high unmet medical needs. Their first FDA-approved product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, targets Demodex blepharitis by addressing the root cause of the disease. Tarsus is also advancing a pipeline of investigational treatments, including TP-04 for papulopustular rosacea and TP-05 for Lyme disease prevention, utilizing a scientific approach to create new treatment categories. The company is committed to advancing science and medicine through awareness, education, and research, with a focus on creating novel therapies.
Target Audience
The primary audience includes patients suffering from Demodex blepharitis, rosacea, and Lyme disease, as well as the healthcare professionals who treat them, such as ophthalmologists and dermatologists.
Features
- XDEMVY® (lotilaner ophthalmic solution) 0.25%: The first and only FDA-approved treatment for Demodex blepharitis.
- TP-04: An investigational treatment for ocular rosacea.
- TP-05: An investigational therapy for the prevention of Lyme disease.
- Commitment to identifying and pursuing the root cause of diseases.
- Focus on diseases with limited treatment options.